What is the expected growth forecast for the Allogeneic Stem Cell Transplantation market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033, driven by increasing demand.

What are the key drivers of the Allogeneic Stem Cell Transplantation market?

Key drivers include advancements in technology and rising incidence of blood disorders, fueling future outlook.

What are the major challenges facing the Allogeneic Stem Cell Transplantation market?

Challenges include high treatment costs, limited donor availability, and risk of graft-versus-host disease.

Which regions are leading the Allogeneic Stem Cell Transplantation market?

North America and Europe are regional leaders, driven by well-established healthcare infrastructure.

Who are the top companies in the Allogeneic Stem Cell Transplantation market?

Top companies include Novartis, Pfizer, and Celgene, which are investing heavily in research and development.

What future opportunities exist in the Allogeneic Stem Cell Transplantation market?

Future opportunities include emerging markets, innovative treatments, and growing demand for regenerative medicine.

How is technology impacting the Allogeneic Stem Cell Transplantation market?

Technology is advancing transplantation procedures, improving patient outcomes, and enhancing the overall future outlook.

What is the current regulatory landscape for the Allogeneic Stem Cell Transplantation market?

The regulatory landscape is evolving, with governments implementing policies to support innovation and patient access.

How will the Allogeneic Stem Cell Transplantation market size change in the next 5 years?

The market size is expected to increase significantly, driven by growing demand and advancements in transplantation technology.

Allogeneic Stem Cell Transplantation - Strategic Insights: Analysis 2025 and Forecasts 2033

Allogeneic Stem Cell Transplantation by Type (/> Unmodified Stem Cell Transplant, T-cell Depleted Transplant, Cord Blood Transplant, Donor Lymphocyte Infusion), by Application (/> Hospital, Ambulatory Surgical Center, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 124

Forecast Period: 2026 - 2033

Market Size: $13.4 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Pages: 124

Forecast Period: 2026 - 2033

Market Size: $13.4 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Allogeneic Stem Cell Transplantation Market Size | CAGR 10.2 Forecast 2033

Allogeneic Stem Cell Transplantation - Strategic Insights: Analysis 2025 and Forecasts 2033

🏭 Healthcare🌍 Global

Pages: 124

Forecast Period: 2026 - 2033

Market Size: $13.4 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Pages: 124

Forecast Period: 2026 - 2033

Market Size: $13.4 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Allogeneic Stem Cell Transplantation Market Overview

The Allogeneic Stem Cell Transplantation market refers to the procedure of transferring stem cells from a donor to a recipient to treat various diseases. As the Allogeneic Stem Cell Transplantation market size is expected to witness significant growth, the growth outlook and market forecast are crucial for industry players. The Allogeneic Stem Cell Transplantation market is poised for industry expansion, driven by increasing demand for stem cell therapies and advancements in transplantation technologies. The scope of the market encompasses various types of transplantations, including bone marrow and peripheral blood stem cell transplantations, and applications such as leukemia, lymphoma, and autoimmune diseases.

Loading chart…

The current Allogeneic Stem Cell Transplantation market size is approximately $1.4 billion. The market is expected to grow at a CAGR of 10.5% during the forecast period, driven by macro drivers such as increasing incidence of blood disorders and advancements in stem cell therapies. Key forces shaping the industry include technology shifts towards more efficient transplantation methods, regulatory approvals for new therapies, and competitive intensity among market players. The largest region for the Allogeneic Stem Cell Transplantation market is North America, while the fastest-growing region is Asia-Pacific. As the market continues to evolve, industry players must stay informed about the latest trends and developments to capitalize on emerging opportunities.

Report Overview

Report Attribute	Details
Market size value in 2025	13.40 million
Revenue forecast in 2033	29.14 million
Growth rate	CAGR of 10.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Mesoblast Limited; Gamida Cell Ltd.; Novartis International AG; Cellectis SA; Magenta Therapeutics Inc.; Fate Therapeutics Inc.; Cynata Therapeutics Limited; Kiadis Pharma N.V; Takeda Pharmaceutical Company Limited; JCR Pharmaceuticals Co., Ltd.; Pluristem Therapeutics Inc.; Celularity Inc.; Lineage Cell Therapeutics Inc.; Nohla Therapeutics Inc.; Orchard Therapeutics Plc
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Allogeneic Stem Cell Transplantation market is poised for significant growth, driven by various factors. The market dynamics section outlines the key growth drivers, restraints, opportunities, and challenges shaping the industry.

Growth Drivers2 items

Increasing demand for Allogeneic Stem Cell Transplantation procedures due to rising incidence of hematological malignancies and autoimmune diseases, driving the Allogeneic Stem Cell Transplantation market size

Advancements in transplantation technologies and techniques, such as ex vivo expansion and in vivo imaging, improving treatment outcomes and contributing to the growth forecast

Restraints2 items

High costs associated with Allogeneic Stem Cell Transplantation procedures, including donor matching, conditioning regimens, and post-transplant care, limiting accessibility and affecting the Allogeneic Stem Cell Transplantation market size

Stringent regulatory requirements and accreditation standards for transplantation centers, posing challenges for new entrants and existing players in the Allogeneic Stem Cell Transplantation market

Opportunities2 items

Emerging markets in Asia-Pacific and Latin America offering significant growth potential for Allogeneic Stem Cell Transplantation due to increasing healthcare expenditure and improving infrastructure, driving the growth forecast

Growing focus on personalized medicine and targeted therapies, creating opportunities for Allogeneic Stem Cell Transplantation to be used in combination with other treatments, expanding the Allogeneic Stem Cell Transplantation market size

Challenges2 items

Managing graft-versus-host disease (GVHD) and other post-transplant complications, which can impact patient outcomes and Allogeneic Stem Cell Transplantation market growth

Addressing the shortage of qualified donors and developing strategies to improve donor recruitment and retention, critical to sustaining the Allogeneic Stem Cell Transplantation market

Market Segmentation

Loading chart…

The Type segment in the Allogeneic Stem Cell Transplantation market refers to the different sources of stem cells used for transplantation. This includes bone marrow, peripheral blood, and cord blood. Each type has its own set of advantages and disadvantages, contributing to the overall market size. Understanding the Allogeneic Stem Cell Transplantation segmentation by type is crucial for market players to develop targeted strategies.

The Application segment in the Allogeneic Stem Cell Transplantation market is categorized into various disease indications, including leukemia, lymphoma, and solid tumors. This segmentation is vital for understanding the market dynamics, as different applications have varying levels of demand and growth prospects. Analyzing the market taxonomy, particularly the Allogeneic Stem Cell Transplantation segmentation by application, helps stakeholders identify opportunities and challenges in the market.

Allogeneic Stem Cell Transplantation Segmentation Breakdown9 items

Type

/> Unmodified Stem Cell Transplant

T-cell Depleted Transplant

Cord Blood Transplant

Donor Lymphocyte Infusion

Application

/> Hospital

Ambulatory Surgical Center

Others

Regional Insights

Loading chart…

The Allogeneic Stem Cell Transplantation market growth is expected to vary across regions, with North America being the largest region, accounting for approximately 40% of the market share. The fastest-growing region is anticipated to be Asia Pacific, driven by increasing adoption of advanced medical technologies, favorable policies, and significant investments in healthcare infrastructure.

Key drivers for North America include a mature ecosystem, high demographics awareness, and established infrastructure. Europe is driven by regional forecast indicating a growing demand for allogeneic stem cell transplantation, policies supporting research and development, and a strong investment landscape. Asia Pacific's growth is fueled by a large and growing patient population, increasing adoption of stem cell therapies, and improving infrastructure.

Latin America and Middle East & Africa are expected to contribute smaller shares to the Allogeneic Stem Cell Transplantation market growth, with key drivers including growing demographics, developing infrastructure, and increasing investment in healthcare. However, these regions also face challenges such as limited adoption and underdeveloped ecosystems.

Competitive Landscape

The Allogeneic Stem Cell Transplantation market is moderately consolidated, driven by a mix of global players and local/regional companies. Key competitive levers include pricing, distribution, product innovation, certifications, and regulatory approvals. The Allogeneic Stem Cell Transplantation competitive landscape is characterized by high competition, with companies focusing on differentiation through technology, service model, and channel strength.

Companies in this market employ various strategies, including M&A, partnerships, product launches, expansion, R&D, and localization, to stay competitive. However, they face challenges such as margin pressure, compliance costs, and supply chain risks. To mitigate these risks, companies focus on strategic initiatives, including regional expansion, innovation pipeline, and premium pricing. Some notable companies and their strategic focuses include:

Mesoblast Limited: regional expansion

Gamida Cell Ltd.: innovation pipeline

Novartis International AG: premium pricing

Cellectis SA: local manufacturing

Magenta Therapeutics Inc.: vertical integration

Fate Therapeutics Inc.: OEM tie-ups

Key Allogeneic Stem Cell Transplantation Companies15 items

Mesoblast Limited

Gamida Cell Ltd.

Novartis International AG

Cellectis SA

Magenta Therapeutics Inc.

Fate Therapeutics Inc.

Cynata Therapeutics Limited

Kiadis Pharma N.V

Takeda Pharmaceutical Company Limited

JCR Pharmaceuticals Co., Ltd.

Pluristem Therapeutics Inc.

Celularity Inc.

Lineage Cell Therapeutics Inc.

Nohla Therapeutics Inc.

Orchard Therapeutics Plc

Market Ecosystem

The Allogeneic Stem Cell Transplantation ecosystem encompasses a complex network of stakeholders involved in the development, manufacturing, and delivery of allogeneic stem cell transplantation services. The ecosystem can be broadly categorized into upstream, midstream, and downstream segments, with value created and captured at various points along the way. Technology providers and suppliers form the upstream segment, while integrators and channels constitute the midstream segment, ultimately serving end users in the downstream segment.

Raw material suppliers — providing stem cells and reagents

OEMs/manufacturers — developing and producing transplantation equipment

Technology providers — offering transplantation protocols and software

System integrators/EPCs — designing and implementing transplantation facilities

Distributors/channel partners — supplying transplantation equipment and services

Service providers/after-sales — providing maintenance and support services

Regulators/standards bodies — establishing and enforcing transplantation standards

In the Allogeneic Stem Cell Transplantation ecosystem, control points are largely influenced by regulators and standards bodies, who dictate the adoption of transplantation services through stringent approvals and guidelines. Dependency risks arise from input constraints, such as the availability of high-quality stem cells, and standards compliance. Switching costs are significant due to the high costs associated with transplantation equipment and facility setup. The ecosystem also differs by region, with varying regulatory frameworks and reimbursement policies affecting the availability and accessibility of allogeneic stem cell transplantation services. A thorough value chain analysis is essential to understand these intricacies and identify opportunities for growth and improvement.

Recent Industry Insights

The Allogeneic Stem Cell Transplantation industry trends have witnessed significant developments over the last 12-18 months. Recent partnerships between key players have focused on advancing research and development in the field. Notable mergers and acquisitions have also taken place, aiming to strengthen market positions and expand product portfolios. Furthermore, several product and technology launches have been announced, showcasing innovative approaches to improve transplantation outcomes and patient care.

Additionally, regulatory changes have been implemented to support the growth of the Allogeneic Stem Cell Transplantation market. A shift in consumer and enterprise trends has also been observed, with an increasing emphasis on personalized medicine and targeted therapies. Several funding rounds and expansions have been reported, providing necessary resources for ongoing research and development efforts. These developments are expected to drive growth and innovation in the Allogeneic Stem Cell Transplantation industry, shaping its future trajectory.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the Allogeneic Stem Cell Transplantation market. The market attractiveness is moderate, driven by increasing demand for effective treatments for hematological malignancies. The competitive intensity is high, with several key players vying for market share. The Allogeneic Stem Cell Transplantation market outlook is promising, with a growing focus on research and development of novel therapies. In terms of innovation landscape, there is a significant focus on improving graft-versus-host disease management and developing more effective conditioning regimens.

The demand-supply balance is expected to be stable, with an increasing number of transplant procedures being performed globally. However, key risk factors include the high cost of transplantation, limited donor availability, and the risk of complications. Overall, the long-term outlook for the Allogeneic Stem Cell Transplantation market is positive, driven by advances in medical technology and an increasing awareness of the benefits of stem cell transplantation.

11 items

1. Executive Summary

2. Allogeneic Stem Cell Transplantation Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Allogeneic Stem Cell Transplantation Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Allogeneic Stem Cell Transplantation Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.1. /> Unmodified Stem Cell Transplant

6.1.2. T-cell Depleted Transplant

6.1.3. Cord Blood Transplant

6.1.4. Donor Lymphocyte Infusion

6.2. Global Allogeneic Stem Cell Transplantation Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.2.1. /> Hospital

6.2.2. Ambulatory Surgical Center

6.2.3. Others

6.3. Global Allogeneic Stem Cell Transplantation Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Allogeneic Stem Cell Transplantation Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Allogeneic Stem Cell Transplantation Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Allogeneic Stem Cell Transplantation Market Competition by Key Manufacturers

8.1. Global Allogeneic Stem Cell Transplantation Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Allogeneic Stem Cell Transplantation: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Mesoblast Limited

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Gamida Cell Ltd.

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Novartis International AG

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Cellectis SA

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Magenta Therapeutics Inc.

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Fate Therapeutics Inc.

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Cynata Therapeutics Limited

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Kiadis Pharma N.V

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Takeda Pharmaceutical Company Limited

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. JCR Pharmaceuticals Co., Ltd.

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Pluristem Therapeutics Inc.

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Celularity Inc.

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Lineage Cell Therapeutics Inc.

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Nohla Therapeutics Inc.

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. Orchard Therapeutics Plc

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Allogeneic Stem Cell Transplantation Market

Figure 4: Global Allogeneic Stem Cell Transplantation Market: Drivers

Figure 5: Global Allogeneic Stem Cell Transplantation Market: Challenges

Figure 6: Global Allogeneic Stem Cell Transplantation Market: Trends

Figure 7: Global Allogeneic Stem Cell Transplantation Market: Opportunity

Figure 8: Global Allogeneic Stem Cell Transplantation Market: Restraint

Figure 9: Global Allogeneic Stem Cell Transplantation Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Allogeneic Stem Cell Transplantation Market Value (USD Million) By Region

Figure 15: Global Allogeneic Stem Cell Transplantation Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Type

Figure 19: Global Market Share (%) By Type (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Application

Figure 21: Global Market Share (%) By Application (2032)

Figure 22: Global Allogeneic Stem Cell Transplantation Market Value (USD Million) By Region

Figure 23: Global Allogeneic Stem Cell Transplantation Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

83 items

Table 1: Market Segmentation Analysis

Table 2: Global Allogeneic Stem Cell Transplantation Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Allogeneic Stem Cell Transplantation Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Allogeneic Stem Cell Transplantation Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Allogeneic Stem Cell Transplantation Market Value (USD Million) By Region

Table 10: Global Allogeneic Stem Cell Transplantation Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Type

Table 13: North America Market Value (USD Million) (2020-2024) By Application

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Type

Table 16: Europe Market Value (USD Million) (2020-2024) By Application

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Type

Table 22: South America Market Value (USD Million) (2020-2024) By Application

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 26: Global Allogeneic Stem Cell Transplantation Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Allogeneic Stem Cell Transplantation Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Allogeneic Stem Cell Transplantation Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Mesoblast Limited Basic Information And Sales Area

Table 31: Mesoblast Limited. Products Portfolio

Table 32: Gamida Cell Ltd. Basic Information And Sales Area

Table 33: Gamida Cell Ltd.. Products Portfolio

Table 34: Novartis International AG Basic Information And Sales Area

Table 35: Novartis International AG. Products Portfolio

Table 36: Cellectis SA Basic Information And Sales Area

Table 37: Cellectis SA. Products Portfolio

Table 38: Magenta Therapeutics Inc. Basic Information And Sales Area

Table 39: Magenta Therapeutics Inc.. Products Portfolio

Table 40: Fate Therapeutics Inc. Basic Information And Sales Area

Table 41: Fate Therapeutics Inc.. Products Portfolio

Table 42: Cynata Therapeutics Limited Basic Information And Sales Area

Table 43: Cynata Therapeutics Limited. Products Portfolio

Table 44: Kiadis Pharma N.V Basic Information And Sales Area

Table 45: Kiadis Pharma N.V. Products Portfolio

Table 46: Takeda Pharmaceutical Company Limited Basic Information And Sales Area

Table 47: Takeda Pharmaceutical Company Limited. Products Portfolio

Table 48: JCR Pharmaceuticals Co., Ltd. Basic Information And Sales Area

Table 49: JCR Pharmaceuticals Co., Ltd.. Products Portfolio

Table 50: Pluristem Therapeutics Inc. Basic Information And Sales Area

Table 51: Pluristem Therapeutics Inc.. Products Portfolio

Table 52: Celularity Inc. Basic Information And Sales Area

Table 53: Celularity Inc.. Products Portfolio

Table 54: Lineage Cell Therapeutics Inc. Basic Information And Sales Area

Table 55: Lineage Cell Therapeutics Inc.. Products Portfolio

Table 56: Nohla Therapeutics Inc. Basic Information And Sales Area

Table 57: Nohla Therapeutics Inc.. Products Portfolio

Table 58: Orchard Therapeutics Plc Basic Information And Sales Area

Table 59: Orchard Therapeutics Plc. Products Portfolio

Table 60: Global Market Value (USD Million) (2025-2032) By Type

Table 61: Global Market Share (%) By Type (2032)

Table 62: Global Market Value (USD Million) (2025-2032) By Application

Table 63: Global Market Share (%) By Application (2032)

Table 64: Global Allogeneic Stem Cell Transplantation Market Value (USD Million) By Region

Table 65: Global Allogeneic Stem Cell Transplantation Market Share (%) By Region (2025-2032)

Table 66: North America Market Value (USD Million) (2025-2032) By Country

Table 67: North America Market Value (USD Million) (2025-2032) By Type

Table 68: North America Market Value (USD Million) (2025-2032) By Application

Table 69: Europe Market Value (USD Million) (2025-2032) By Country

Table 70: Europe Market Value (USD Million) (2025-2032) By Type

Table 71: Europe Market Value (USD Million) (2025-2032) By Application

Table 72: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 73: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 74: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 75: South America Market Value (USD Million) (2025-2032) By Country

Table 76: South America Market Value (USD Million) (2025-2032) By Type

Table 77: South America Market Value (USD Million) (2025-2032) By Application

Table 78: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 79: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 80: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 81: Research Programs/Design For This Report

Table 82: Key Data Information From Secondary Sources

Table 83: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Allogeneic Stem Cell Transplantation Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	13.40 million
Revenue forecast in 2033	29.14 million
Growth rate	CAGR of 10.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Mesoblast Limited; Gamida Cell Ltd.; Novartis International AG; Cellectis SA; Magenta Therapeutics Inc.; Fate Therapeutics Inc.; Cynata Therapeutics Limited; Kiadis Pharma N.V; Takeda Pharmaceutical Company Limited; JCR Pharmaceuticals Co., Ltd.; Pluristem Therapeutics Inc.; Celularity Inc.; Lineage Cell Therapeutics Inc.; Nohla Therapeutics Inc.; Orchard Therapeutics Plc
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options